Abstract:The transient receptor potential vanilloid type 1 (TRPV1) is a heat-activated cation channel protein, which contributes to inflammation, acute and persistent pain. Antagonists of human TRPV1 (hTRPV1) represent a novel therapeutic approach for the treatment of pain. Developing various antagonists of hTRPV1, however, has been hindered by the unavailability of a 3D structure of hTRPV1. Recently, the 3D structures of rat TRPV1 (rTRPV1) in the presence and absence of ligand have been reported as determined by cryo-EM. rTRPV1 shares 85.7% sequence identity with hTRPV1. In the present work, we constructed and reported the 3D homology tetramer model of hTRPV1 based on the cryo-EM structures of rTRPV1. Molecular dynamics (MD) simulations, energy minimizations, and prescreen were applied to select and validate the best model of hTRPV1. The predicted binding pocket of hTRPV1 consists of two adjacent monomers subunits, which were congruent with the experimental rTRPV1 data and the cyro-EM structures of rTRPV1. The detailed interactions between hTRPV1 and its antagonists or agonists were characterized by molecular docking, which helped us to identify the important residues. Conformational changes of hTRPV1 upon antagonist/agonist binding were also explored by MD simulation. The different movements of compounds led to the different conformational changes of monomers in hTRPV1, indicating that TRPV1 works in a concerted way, resembling some other channel proteins such as aquaporins. We observed that the selective filter was open when hTRPV1 bound with an agonist during MD simulation. For the lower gate of hTRPV1, we observed large similarities between hTRPV1 bound with antagonist and with agonist. A five-point pharmacophore model based on several antagonists was established, and the structural model was used to screen in silico for new antagonists for hTRPV1. By using the 3D TRPV1 structural model above, the pilot in silico screening has begun to yield promising hits with activity as hTRPV1 antagonists, several of which showed substantial potency.

A Retrospective Look at the Impact of Binding Site Environment on the Optimization of TRPA1 Antagonists.

Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action Via Cryogenic Electron Microscopy

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Transient receptor potential ankyrin 1 (TRPA1) modulators: Recent update and future perspective

P2X7 receptors exhibit at least three modes of allosteric antagonism

Distinctive Drug Binding Sites and Gating Mechanisms of the Nociceptive Ion Channel TRPA1

Discovery of a Potent (4R,5S)-4-Fluoro-5-Methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonist and its Methylene Phosphate Prodrug Guided By Molecular Modeling.

Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Identification of a Binding Site for Small Molecule Inhibitors Targeting Human TRPM4

Structural Pharmacology of TRPV4 Antagonists

Insight into the Structure of Tetramer Htrpv1 from Homology Modeling, Molecular Docking, Molecular Dynamics Simulation and Virtual Screening

An Insight into Antagonist Binding and Induced Conformational Dynamics of Class B GPCR Corticotropin-Releasing Factor Receptor 1.

Α-Aryl Pyrrolidine Sulfonamides As TRPA1 Antagonists

Three-Dimensional Quantitative Structure-Activity Relationship Study of Transient Receptor Potential Vanilloid 1 Channel Antagonists Reveals Potential for Drug Design Purposes

Structural Insights into Selective and Dual Antagonism of EP2 and EP4 Prostaglandin Receptors

Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy

Structural insights into the human P2X1 receptor and ligand interactions

Residues remote from the binding pocket control the antagonist selectivity towards the corticotropin-releasing factor receptor-1

Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient receptor potential channel A1 (TRPA1) antagonists.

β-Lactam TRPM8 Antagonists Derived from Phe-Phenylalaninol Conjugates: Structure-Activity Relationships and Antiallodynic Activity